2-Acetamido-3-ethoxy-3-oxo-2-(pyridin-4-ylmethyl)propanoic acid | 195877-36-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Acetamido-3-ethoxy-3-oxo-2-(pyridin-4-ylmethyl)propanoic acid
• CAS: 195877-36-2
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: WYFUROOPDIAKNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  529.0±50.0 °C(Predicted)
• 密度：
  1.282±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-Acetamido-3-ethoxy-3-oxo-2-(pyridin-4-ylmethyl)propanoic acid 在 palladium on activated charcoal 盐酸 、 氢气 、 copper(II) sulfate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 41.5h， 生成 3-(1-Cbz-4-哌啶)-2-(boc-氨基)丙酸
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1
• 作为产物：
  描述：

  4-氯甲基吡啶 在 氢氧化钾 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 2-Acetamido-3-ethoxy-3-oxo-2-(pyridin-4-ylmethyl)propanoic acid
  参考文献：
  名称：

  Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety

  摘要：

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00179-1

文献信息

• SERINE PROTEASE INHIBITORS
  申请人：Akzo Nobel N.V.

  公开号：EP1012164A1

  公开（公告）日：2000-06-28
• DERIVES DE 2-AMINO-4-PYRIDYLMETHYL-THIAZOLINE ET LEUR UTILISATION COMME INHIBITEURS DE NO-SYNTHASE INDUCTIBLE
  申请人：Aventis Pharma S.A.

  公开号：EP1450750B1

  公开（公告）日：2009-10-21
• US6218365B1
  申请人：——

  公开号：US6218365B1

  公开（公告）日：2001-04-17
• [EN] SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA SERINE-PROTEASE
  申请人：——

  公开号：WO1997031939A1

  公开（公告）日：1997-09-04

  [EN] The invention relates to a compound having formula (I), wherein A, B, X, Y and r are as defined in the description, or a prodrug thereof or a pharmaceutically acceptable salt thereof. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.
  [FR] L'invention concerne un composé de la formule (I). Dans cette formule, A, B, X, Y et r sont comme définis dans la description. L'invention concerne également un précurseur de ce composé ou un sel de celui-ci acceptable sur le plan pharmaceutique. Le composé de l'invention a une activité d'anticoagulant et il peut être utilisé pour traiter ou prévenir des maladies associées à la thrombine.
• Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety
  作者：Anton E.P. Adang、Co A.M. Peters、Siene Gerritsma、Edwin de Zwart、Gerrit Veeneman

  DOI：10.1016/s0960-894x(99)00179-1

  日期：1999.5

  2-Amino-3-piperidin-4-yl-propionic acid containing peptidomimetics are potent protease inhibitors when combined with an appropriate keto-thiazole or keto-carboxylic acid moiety. A novel P-1 residue in factor Xa and thrombin inhibitors has been found resulting in IC50 values as low as 0.048 mu M, a factor of ten more potent than Argatroban. Starting with non-chiral synthetic routes, a new stereospecific route was developed as well as a new solid-phase method. (C) 1999 Elsevier Science Ltd. All rights reserved.